COVID-19: SARS-CoV-2-CZ-PREVAL-II Study

Summary

The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.

Conditions

• COVID-19
• SARS-CoV-2 Infection

Interventions

DIAGNOSTIC_TEST

Quantitative analysis of SARS-CoV-2 antibodies

The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).

DIAGNOSTIC_TEST

Cellular immunity

Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.

Sponsors & Collaborators

• Ministry of Health, Czech Republic

  collaborator OTHER_GOV

• The National Institute of Public Health

  collaborator UNKNOWN

• The Institute of Molecular and Translational Medicine, Czech Republic

  collaborator OTHER

• University Hospital Olomouc

  collaborator OTHER

• Institute for Clinical and Experimental Medicine

  collaborator OTHER_GOV

• Thomayer University Hospital

  collaborator OTHER

• Czech Academy of Sciences

  collaborator OTHER

• Palacky University

  collaborator OTHER

• Institute of Health Information and Statistics of the Czech Republic

  lead OTHER_GOV

Principal Investigators

• Marián Hajdúch, Assoc. Prof. · Institute of Molecular nad Translational Medicine

• Věra Adámková, Prof. · Institute for Clinical and Experimental Medicine

• Markéta Ibrahimová, Ph.D. · Thomayer University Hospital

• Barbora Macková, M.D. · The National Institute of Public Health

• Ladislav Dušek, Prof. · Institute of Health Information and Statistics of the Czech Republic

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-09-13

Primary Completion

2021-10-31

Completion

2022-02-24

Countries

• Czechia

Study Locations